Chemometec A/S (CHEMM.CO) Stock Price

Chemometec A/S Price

OMX·CLOSED
477.20DKK-0.80 (-0.17 %)
Market closed

Revenue has compounded at 20.4% per year over the past 19 years to 495.57 M DKK. Earnings per share have grown at 21.8% per year over the last 19 years. Chemometec A/S's net margin stands at 37.6%, up from 31.4% several years earlier. Chemometec A/S currently offers a dividend yield of about 1.47%. The payout ratio is around 65% of earnings. Analysts set a median price target of 900.15 DKK, implying 88.6% above the current price. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 109% above its 52-week low.

Chemometec A/S stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Chemometec A/S over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Chemometec A/S stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Chemometec A/S's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Chemometec A/S Stock Price History
DateChemometec A/S Price
8/13/2026477.20 DKK
8/12/2026478.00 DKK
8/11/2026475.00 DKK
8/10/2026466.40 DKK
8/7/2026430.00 DKK
8/6/2026415.00 DKK
8/5/2026414.20 DKK
8/4/2026418.00 DKK
7/31/2026432.60 DKK
7/30/2026430.80 DKK
7/29/2026429.80 DKK
7/28/2026405.60 DKK
7/27/2026412.00 DKK
7/24/2026407.40 DKK
7/23/2026406.80 DKK
7/22/2026405.00 DKK
7/21/2026407.00 DKK
7/20/2026416.20 DKK
7/17/2026421.60 DKK
7/16/2026423.60 DKK
7/15/2026417.40 DKK
7/14/2026410.60 DKK
7/13/2026404.40 DKK
7/10/2026409.80 DKK
7/9/2026409.60 DKK
7/8/2026398.20 DKK
7/7/2026405.00 DKK
7/6/2026409.60 DKK
7/3/2026406.00 DKK
7/2/2026406.80 DKK
7/1/2026405.80 DKK
6/30/2026362.20 DKK
6/29/2026365.20 DKK
6/26/2026370.60 DKK
6/25/2026369.20 DKK
6/24/2026366.40 DKK
6/23/2026371.00 DKK
6/22/2026370.00 DKK
6/19/2026378.60 DKK
6/18/2026383.40 DKK
6/17/2026379.00 DKK
6/16/2026377.20 DKK
6/15/2026381.00 DKK
6/12/2026376.40 DKK
6/11/2026380.80 DKK
6/10/2026370.00 DKK
6/9/2026383.60 DKK
6/8/2026370.80 DKK
6/4/2026369.20 DKK
6/3/2026357.00 DKK
6/2/2026369.60 DKK
6/1/2026363.20 DKK
5/29/2026367.00 DKK
5/28/2026346.60 DKK
5/27/2026352.80 DKK
5/26/2026348.40 DKK
5/22/2026337.20 DKK
5/21/2026337.40 DKK
5/20/2026332.60 DKK
5/19/2026323.80 DKK
5/18/2026323.20 DKK
5/13/2026313.40 DKK
5/12/2026320.60 DKK
5/11/2026316.00 DKK
5/8/2026314.80 DKK
5/7/2026322.20 DKK
5/6/2026321.60 DKK
5/5/2026305.00 DKK
5/4/2026323.40 DKK
5/1/2026326.00 DKK
4/30/2026320.00 DKK
4/29/2026320.00 DKK
4/28/2026318.80 DKK
4/27/2026328.20 DKK
4/24/2026327.40 DKK
4/23/2026326.60 DKK
4/22/2026342.20 DKK
4/21/2026346.00 DKK
4/20/2026345.00 DKK
4/17/2026350.00 DKK
4/16/2026336.80 DKK
4/15/2026330.60 DKK
4/14/2026323.00 DKK
4/13/2026302.60 DKK
4/10/2026303.40 DKK
4/9/2026300.20 DKK
4/8/2026305.80 DKK
4/7/2026293.40 DKK
4/1/2026309.00 DKK
3/31/2026300.80 DKK
3/30/2026294.60 DKK
3/27/2026290.00 DKK
3/26/2026297.00 DKK
3/25/2026280.60 DKK
3/24/2026236.80 DKK
3/20/2026236.80 DKK
3/19/2026234.19 DKK
3/18/2026239.53 DKK
3/17/2026245.24 DKK
3/16/2026237.87 DKK
3/13/2026237.39 DKK
3/12/2026237.99 DKK
3/11/2026238.58 DKK
3/10/2026249.87 DKK
3/9/2026243.45 DKK
3/6/2026245.95 DKK
3/5/2026249.87 DKK
3/4/2026254.62 DKK
3/3/2026241.08 DKK
3/2/2026243.93 DKK
2/27/2026249.75 DKK
2/26/2026245.35 DKK
2/25/2026228.84 DKK
2/24/2026229.31 DKK
2/23/2026231.22 DKK
2/20/2026237.63 DKK
2/19/2026235.85 DKK
2/18/2026243.33 DKK
2/17/2026238.94 DKK
2/16/2026238.11 DKK
2/13/2026239.65 DKK
2/12/2026241.67 DKK
2/11/2026234.66 DKK
2/10/2026245.35 DKK
2/9/2026241.79 DKK
2/6/2026256.64 DKK
2/5/2026275.06 DKK
2/4/2026344.27 DKK
2/3/2026364.17 DKK
2/2/2026360.31 DKK
1/30/2026362.09 DKK
1/29/2026362.69 DKK
1/28/2026380.21 DKK
1/27/2026392.69 DKK
1/26/2026396.55 DKK
1/23/2026406.35 DKK
1/22/2026417.93 DKK
1/21/2026408.43 DKK
1/20/2026411.70 DKK
1/19/2026407.54 DKK
1/16/2026422.98 DKK
1/15/2026415.86 DKK
1/14/2026421.20 DKK
1/13/2026429.52 DKK
1/12/2026427.44 DKK
1/9/2026422.69 DKK
1/8/2026426.25 DKK
1/7/2026409.62 DKK
1/6/2026417.64 DKK
1/5/2026405.76 DKK
1/2/2026400.71 DKK
12/30/2025408.43 DKK
12/29/2025409.32 DKK
12/23/2025406.05 DKK
12/22/2025401.30 DKK
12/19/2025405.16 DKK
12/18/2025395.06 DKK
12/17/2025386.45 DKK
12/16/2025398.63 DKK
12/15/2025407.84 DKK
12/12/2025416.45 DKK
12/11/2025430.41 DKK
12/10/2025428.63 DKK
12/9/2025433.08 DKK
12/8/2025436.05 DKK
12/5/2025440.81 DKK
12/4/2025445.26 DKK
12/3/2025449.12 DKK
12/2/2025454.17 DKK
12/1/2025453.88 DKK
11/28/2025464.87 DKK
11/27/2025464.57 DKK
11/26/2025460.41 DKK
11/25/2025457.44 DKK
11/24/2025449.72 DKK
11/21/2025446.45 DKK
11/20/2025451.50 DKK
11/19/2025446.75 DKK
11/18/2025445.56 DKK
11/17/2025448.53 DKK
11/14/2025455.06 DKK
11/13/2025456.55 DKK
11/12/2025462.49 DKK
11/11/2025443.18 DKK
11/10/2025436.35 DKK
11/7/2025412.29 DKK
11/6/2025423.28 DKK
11/5/2025432.79 DKK
11/4/2025459.82 DKK
11/3/2025469.03 DKK
10/31/2025469.92 DKK
10/30/2025470.51 DKK
10/29/2025462.79 DKK
10/28/2025443.18 DKK
10/27/2025428.63 DKK
10/24/2025415.86 DKK
10/23/2025414.07 DKK
10/22/2025405.46 DKK
10/21/2025411.10 DKK
10/20/2025409.02 DKK
10/17/2025398.03 DKK
10/16/2025389.12 DKK
10/15/2025384.67 DKK
10/14/2025387.34 DKK
10/13/2025392.98 DKK
10/10/2025403.08 DKK
10/9/2025408.73 DKK
10/8/2025411.99 DKK
10/7/2025412.89 DKK
10/6/2025404.87 DKK
10/3/2025402.79 DKK
10/2/2025388.53 DKK
10/1/2025385.26 DKK
9/30/2025370.71 DKK
9/29/2025373.68 DKK
9/26/2025369.52 DKK
9/25/2025369.52 DKK
9/24/2025379.32 DKK
9/23/2025383.18 DKK
9/22/2025389.42 DKK
9/19/2025387.93 DKK
9/18/2025386.45 DKK
9/17/2025381.10 DKK
9/16/2025374.57 DKK
9/15/2025375.16 DKK
9/12/2025362.09 DKK
9/11/2025321.99 DKK
9/10/2025332.98 DKK
9/9/2025322.59 DKK
9/8/2025318.43 DKK
9/5/2025321.99 DKK
9/4/2025313.08 DKK
9/3/2025308.92 DKK
9/2/2025305.36 DKK
9/1/2025310.70 DKK
8/29/2025309.52 DKK
8/28/2025310.41 DKK
8/27/2025306.25 DKK
8/26/2025306.25 DKK
8/25/2025308.03 DKK
8/22/2025312.78 DKK
8/21/2025305.95 DKK
8/20/2025308.62 DKK
8/19/2025305.36 DKK
8/18/2025301.50 DKK
8/15/2025297.63 DKK
Access this data via the Eulerpool API
Get Free API Key

Chemometec A/S Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
444.40 M DKK
228.51 M DKK
178.67 M DKK
Jan 1, 2024
407.87 M DKK
178.78 M DKK
136.28 M DKK
Jan 1, 2025
495.57 M DKK
247.68 M DKK
186.41 M DKK
Jan 1, 2026 (e)
515.00 M DKK
237.85 M DKK
197.75 M DKK
Jan 1, 2027 (e)
562.33 M DKK
260.97 M DKK
217.76 M DKK
Jan 1, 2028 (e)
653.88 M DKK
302.57 M DKK
268.56 M DKK
Jan 1, 2029 (e)
709.00 M DKK
328.08 M DKK
278.44 M DKK
Jan 1, 2030 (e)
793.00 M DKK
366.95 M DKK
313.25 M DKK

Chemometec A/S Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 1:15 AM
 
REVENUEM DKK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM DKK
EBITM DKK
EBIT MARGIN%
NET INCOMEM DKK
NET INCOME GROWTH%
DIV.DKK
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
61.0085.0090.00112.00175.00214.00281.00428.00444.00407.00495.00515.00562.00653.00709.00793.00
35.5639.345.8824.4456.2522.2931.3152.313.74-8.3321.624.049.1316.198.5811.85
85.2584.7188.8988.3990.2990.1990.0489.7288.9690.1793.9493.9493.9493.9493.9493.94
52.0072.0080.0099.00158.00193.00253.00384.00395.00367.00465.00483.79527.94613.42666.03744.94
5.0015.0011.0024.0054.0077.00116.00204.00228.00178.00247.00237.00260.00302.00328.00366.00
8.2017.6512.2221.4330.8635.9841.2847.6651.3543.7349.9046.0246.2646.2546.2646.15
7.0010.007.0018.0041.0059.0088.00159.00178.00136.00186.00197.00217.00268.00278.00313.00
600.0042.86-30.00157.14127.7843.9049.1580.6811.95-23.6036.765.9110.1523.503.7312.59
––––7.5014.504.004.006.004.007.007.007.007.00––
–––––93.33-72.41–50.00-33.3375.00–––––
15.6515.2915.6215.3416.3417.4017.4017.4017.4217.4017.4017.4017.4017.4017.4017.40
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Chemometec A/S generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Chemometec A/S retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Chemometec A/S's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Chemometec A/S has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Chemometec A/S's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Chemometec A/S stock margins

The Chemometec A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chemometec A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chemometec A/S.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
90.12 %
41.27 %
31.43 %
Jan 1, 2022
89.70 %
47.79 %
37.23 %
Jan 1, 2023
88.97 %
51.42 %
40.20 %
Jan 1, 2024
90.13 %
43.83 %
33.41 %
Jan 1, 2025
93.93 %
49.98 %
37.61 %
Jan 1, 2026 (e)
93.93 %
46.19 %
38.40 %
Jan 1, 2027 (e)
93.93 %
46.41 %
38.72 %
Jan 1, 2028 (e)
93.93 %
46.27 %
41.07 %

Chemometec A/S Stock Revenue, EBIT, Earnings per Share

The Chemometec A/S earnings per share therefore indicates how much revenue Chemometec A/S has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
16.15 DKK
6.67 DKK
5.08 DKK
Jan 1, 2022
24.62 DKK
11.76 DKK
9.16 DKK
Jan 1, 2023
25.51 DKK
13.12 DKK
10.26 DKK
Jan 1, 2024
23.44 DKK
10.28 DKK
7.83 DKK
Jan 1, 2025
28.48 DKK
14.23 DKK
10.71 DKK
Jan 1, 2026 (e)
29.59 DKK
13.67 DKK
11.36 DKK
Jan 1, 2027 (e)
32.31 DKK
15.00 DKK
12.51 DKK
Jan 1, 2028 (e)
37.57 DKK
17.39 DKK
15.43 DKK

Chemometec A/S business model & stock analysis

Chemometec A/S is an internationally active company based in Allerød, Denmark, specializing in the development and distribution of instruments and solutions for cell counting and analysis. The company was founded in 1997 by Tine Kjeldsen and Steen Søndergaard and has since had a remarkable growth story.

Chemometec A/S SWOT Analysis

Strengths

Chemometec A/S has a strong reputation in the market for their innovative products and technologies.

The company has a highly skilled and knowledgeable workforce, which enables them to develop and deliver high-quality solutions.

Chemometec A/S has a wide range of product offerings, catering to various industries and customer needs.

Weaknesses

One weakness of Chemometec A/S is their reliance on a limited number of suppliers, which could result in supply chain disruptions.

The company may face challenges in scaling their production capacity to meet increasing market demand.

Chemometec A/S lacks strong brand recognition compared to some of their competitors.

Opportunities

There is a growing demand for advanced technologies in the healthcare sector, which presents an opportunity for Chemometec A/S to expand their market share.

The company can explore strategic partnerships and collaborations to leverage their expertise and access new markets.

Chemometec A/S can invest in research and development to continually innovate and develop new products that meet emerging customer needs.

Threats

Intense competition in the industry poses a threat to Chemometec A/S, as competitors may offer similar products at lower prices.

Evolving regulations and compliance requirements could impact the company's operations and increase costs.

Changes in market trends and customer preferences may require Chemometec A/S to adapt quickly in order to remain competitive.

Chemometec A/S Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Chemometec A/S historical P/E ratio, EBIT multiple, and P/S ratio

Chemometec A/S annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Chemometec A/S shares outstanding

The number of shares of Chemometec A/S was 17.4 M in 2025. This indicates how many shares Chemometec A/S is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
17.40 M Stocks
Jan 1, 2022
17.40 M Stocks
Jan 1, 2023
17.42 M Stocks
Jan 1, 2024
17.40 M Stocks
Jan 1, 2025
17.40 M Stocks
Jan 1, 2026 (e)
17.40 M Stocks
Jan 1, 2027 (e)
17.40 M Stocks
Jan 1, 2028 (e)
17.40 M Stocks

Chemometec A/S Dividend History

7 years of dividend payments

YearAnnual DividendYoY ChangePayments
20257.00DKK↑ 75.0%1×
Oct 10, 20257.00DKK↑ 75.0%1/1
20244.00DKK↓ 33.3%1×
20236.00DKK↑ 50.0%1×
20224.00DKK 0.0%—
20214.00DKK↓ 72.4%1×
202014.50DKK↑ 93.3%2×
20197.50DKK—1×

Chemometec A/S dividend history and estimates

In 2025, Chemometec A/S paid a dividend amounting to 7.00 DKK. Dividend means that Chemometec A/S distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021
4.00 DKK
0.00 DKK
0.00 DKK
Jan 1, 2022
4.00 DKK
0.00 DKK
0.00 DKK
Jan 1, 2023 (e)
0.00 DKK
6.00 DKK
0.00 DKK
Jan 1, 2024
4.00 DKK
0.00 DKK
0.00 DKK
Jan 1, 2025
7.00 DKK
0.00 DKK
0.00 DKK
Jan 1, 2026
7.00 DKK
0.00 DKK
0.00 DKK
Jan 1, 2027 (e)
0.00 DKK
7.00 DKK
0.00 DKK
Jan 1, 2028 (e)
0.00 DKK
7.00 DKK
0.00 DKK

Chemometec A/S dividend payout ratio

In 2025, Chemometec A/S had a payout ratio of 65.35%. The payout ratio indicates the percentage of the company's profits that Chemometec A/S distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
78.79 %
Jan 1, 2022
58.31 %
Jan 1, 2023
58.50 %
Jan 1, 2024
51.07 %
Jan 1, 2025
65.35 %
Jan 1, 2026 (e)
61.60 %
Jan 1, 2027 (e)
55.94 %
Jan 1, 2028 (e)
45.36 %

Current Chemometec A/S forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
91.67 % (11)
Hold
8.33 % (1)
Sell
0.00 % (0)
12M Price Target
900.15
Last Price
477.20
Currency
DKK
12M Return Potential
88.63 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Chemometec A/S stock

30/100
26
Environment
57
Social
7
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Chemometec A/S shareholder structure

% Name
3.89486%
Berenberg Bank (Asset Management)
Berenberg Bank (Asset Management)
3.64046%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
3.57861%
SEB Investment Management AB
SEB Investment Management AB
3.25757%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
3.11971%
Handelsbanken Kapitalförvaltning AB
Handelsbanken Kapitalförvaltning AB
2.99221%
The Vanguard Group, Inc.
The Vanguard Group, Inc.

Chemometec A/S Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.2%
Float Shares
-
Shares Outstanding
-

Chemometec A/S Executives and Management Board

7 members · avg. age 53 · 29 % women

MB

Mr. Martin Behrens (32)

Chief Executive Officer

6.40 M DKK

Management

KN

Mr. Kim Nicolajsen (44)

Chief Financial Officer

3.15 M DKK

Board of Directors

NT

Mr. Niels Thestrup (61)

Chairman of the Board · since 2021

800,000.00 DKK
MG

Mr. Martin Glensbjerg (64)

Vice Chairman of the Board · since 2001

360,000.00 DKK
BH

Ms. Betina Hagerup (62)

Independent Director

340,000.00 DKK
KF

Ms. Kristine Faerch (47)

Independent Director

300,000.00 DKK
PR

Mr. Peter Reich (61)

Independent Director

280,000.00 DKK

Chemometec A/S Supply Chain

Chemometec A/S Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#Nameβ 1YTrend
1
Beam Therapeutics
Customer·Biotechnology·US
0.44
0.84
0.31
-0.01
0.62
0.64
0.55
2
Roche Holding
Supplier·Customer·Pharmaceuticals·CH
-0.60
0.72
0.23
0.11
-0.08
0.64
-0.03
3
Celcuity
Customer·Biotechnology·US
0.45
0.62
0.35
-0.06
0.56
0.56
1.14
4
Showa Denko
Customer·Chemicals·JP
0.41
0.52
0.09
0
0.40
0.50
0.42
5
Krystal Biotech
Customer·Biotechnology·US
0.50
0.72
0.77
0.70
-0.30
0.32
-0.15
#Nameβ 1YTrend
1
Emergent BioSolutions
Customer·Biotechnology·US
0.72
0.64
0.68
-0.06
0.40
-0.76
—

Frequently asked questions about Chemometec A/S

The business model of Chemometec A/S is focused on providing advanced solutions for cellular analysis and diagnostics. The company specializes in developing and manufacturing instruments that enable users to quantify and analyze cells for various purposes, such as cell counting, size measurement, viability assessment, and cell cycle analysis. Chemometec A/S's innovative technologies and products cater to a wide range of industries, including biopharmaceuticals, life sciences research, clinical diagnostics, and industrial manufacturing. With a strong emphasis on accuracy, reliability, and user-friendliness, Chemometec A/S aims to support its customers in improving their research outcomes and diagnostic capabilities.

Chemometec A/S is primarily active in the biotechnology and life sciences industries.

The main competitors of Chemometec A/S in the market are Beckman Coulter, Inc., Sysmex Corporation, and Becton, Dickinson and Company.

Chemometec A/S is a Danish biotechnology company founded in 1997. With headquarters in Allerød, Denmark, the company specializes in developing and manufacturing innovative instruments and software solutions for cell counting and analysis. Chemometec A/S has established itself as a leading provider of automated cell counters, offering high-quality and reliable products to the global scientific community. The company has garnered significant recognition for its unique imaging technology and advanced image analysis algorithms. Over the years, Chemometec A/S has expanded its product portfolio, ensuring accurate cell counting and viability assessment, particularly in the fields of hematology, microbiology, and life sciences.

Some significant milestones achieved by Chemometec A/S include the development and commercialization of their flagship product, the NucleoCounter® system, which revolutionized cell counting and viability analysis in life science research and industry. The company also expanded its product portfolio with the introduction of the NucleoCassette™ and NucleoView™ software, enhancing the efficiency and accuracy of cell analysis further. Chemometec A/S successfully established a global presence, with offices and distributors in key markets worldwide, consolidating its position as a leading provider of innovative solutions for cell analysis. Through continuous investment in research and development, the company continues to deliver groundbreaking technologies to support scientific advancements.

Chemometec A/S is primarily present in several countries and regions worldwide. The company operates in various regions, including Europe, North America, Asia-Pacific, and the Middle East. Some specific countries where Chemometec A/S has a significant presence are Denmark, the United States, China, Germany, India, Japan, and many others. With its global reach, Chemometec A/S aims to serve customers and expand its market presence across different economies.

Chemometec A/S represents strong values and a clear corporate philosophy. The company prioritizes innovation, scientific excellence, and customer satisfaction. With a focus on providing advanced solutions for cell counting and analysis, Chemometec A/S is committed to delivering accurate, reliable, and user-friendly products. They strive to empower researchers and laboratories with cutting-edge technologies that enhance efficiency and productivity. By continuously investing in research and development, Chemometec A/S ensures that their customers have access to the latest advancements in cell analysis. With their commitment to quality and customer-centric approach, Chemometec A/S aims to be a trusted partner in the field of life sciences.

Analysts currently set an average price target of 883.58 DKK for the Chemometec A/S stock (median: 900.15 DKK), implying +85.2 % versus the latest price. The consensus is based on 12 analyst ratings.

Chemometec A/S Analyst Price Targets 2026

12 analysts currently rate the Chemometec A/S stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Chemometec A/S to generate revenue of 515.00 M DKK and earnings per share of 11.36 DKK.

Chemometec A/S Analyst Price Targets 2026

Converted at the current exchange rate, the Chemometec A/S share trades at 63.84 EUR (477.20 DKK).

The Chemometec A/S share (CHEMM.CO) is listed on 6 stock exchanges, including: Frankfurt (CHY.F), München (CHY.MU), Düsseldorf (CHY.DU), London (0DZ0.L).

Chemometec A/S is a Danish biotech company that offers innovative solutions and products for cell analysis in the fields of Hematology, Oncology, and Stem Cell Research. Their core product is the NucleoCounter platform, which includes automated cell counters with patented technology for precise counting and sizing of cells. The company serves various customers, including research institutions, clinical labs, hospitals, biotech and pharma companies, and contract research organizations. They aim to provide solutions that help customers achieve their scientific and clinical goals faster, more reliably, and at a lower cost.

The expected revenue of Chemometec A/S is 515.00 M DKK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Chemometec A/S is 197.75 M DKK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Chemometec A/S is currently 41.99. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Chemometec A/S stock.

The price-to-sales ratio (P/S) of Chemometec A/S is currently 16.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Chemometec A/S stock.

The Eulerpool Quality Score for Chemometec A/S is 7/10.

The ISIN of Chemometec A/S is DK0060055861. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Chemometec A/S is A0MS80. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Chemometec A/S is CHEMM.CO. The ticker symbol is used to trade Chemometec A/S shares on the stock exchange.

Over the past 12 months, Chemometec A/S paid a dividend of 7.00 DKK . This corresponds to a dividend yield of about 1.47 %. For the coming 12 months, Chemometec A/S is expected to pay a dividend of 7.00 DKK.

The current dividend yield of Chemometec A/S is 1.47 %.

Chemometec A/S pays a dividend, distributed in the months of , , , .

Chemometec A/S paid dividends every year for the past 3 years.

For the upcoming 12 months, dividends amounting to 7.00 DKK are expected. This corresponds to a dividend yield of 1.47 %.

Chemometec A/S is assigned to the 'Health' sector.

To receive the latest dividend of Chemometec A/S from amounting to 7 DKK, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Chemometec A/S distributed 6 DKK as dividends.

The dividends of Chemometec A/S are distributed in DKK.

All fundamentals and in-depth analysis of Chemometec A/S

Our stock analysis for Chemometec A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chemometec A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Chemometec A/S Stock
Chemometec A/S Revenue→
Chemometec A/S Stock
Chemometec A/S Net Income→
Chemometec A/S Stock
Chemometec A/S P/E→
Chemometec A/S Stock
Chemometec A/S P/S→
Chemometec A/S Stock
Chemometec A/S EBIT→
Chemometec A/S Stock
Chemometec A/S Dividend→
Chemometec A/S Stock
Chemometec A/S Directors Dealings→
Chemometec A/S Stock
Chemometec A/S Stocks→
Chemometec A/S Stock
Chemometec A/S Market capitalization→
Chemometec A/S Stock
Chemometec A/S Debt→
Chemometec A/S Stock
Chemometec A/S Liabilities→
Chemometec A/S Stock
Chemometec A/S Equity→
Chemometec A/S Stock
Chemometec A/S AAQS→
Chemometec A/S Stock
Chemometec A/S Employees→
Chemometec A/S Stock
Chemometec A/S ROE→
Chemometec A/S Stock
Chemometec A/S ROA→
Chemometec A/S Stock
Chemometec A/S ROCE→
Chemometec A/S Stock
Chemometec A/S News→
Chemometec A/S Stock
Chemometec A/S Analyst Price Targets→

Health Stocks

ChemPartner PharmaTech CoChemomab Therapeutics Ltd DRCChengda Pharmaceuticals CoChemedChengdu Easton Biopharmaceuticals CoChemclin Diagnostics CoChengdu huasun technology group Inc LTDCheckpoint TrendsChengdu Kanghong Pharmaceutical Group CoCheck CapChengdu Kanghua Biological Products CoCHC Healthcare GroupAll Stocks A–Z →